| __timestamp | Ligand Pharmaceuticals Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 612613000000 |
| Thursday, January 1, 2015 | 24378000 | 650773000000 |
| Friday, January 1, 2016 | 26621000 | 619061000000 |
| Sunday, January 1, 2017 | 28653000 | 628106000000 |
| Monday, January 1, 2018 | 37734000 | 717599000000 |
| Tuesday, January 1, 2019 | 41884000 | 964737000000 |
| Wednesday, January 1, 2020 | 64435000 | 875663000000 |
| Friday, January 1, 2021 | 57483000 | 886361000000 |
| Saturday, January 1, 2022 | 70062000 | 997309000000 |
| Sunday, January 1, 2023 | 52790000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial strategies of major players is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Takeda, a global leader, consistently shows SG&A expenses in the range of hundreds of billions, peaking at approximately 1.05 trillion in 2023. In contrast, Ligand, a smaller entity, exhibits a more modest yet significant growth, with expenses increasing by over 130% from 2014 to 2022, reaching a high of 70 million. This stark contrast highlights the scale and operational strategies of these companies. Notably, Takeda's expenses surged by nearly 72% from 2014 to 2023, reflecting its expansive global operations. Missing data for Ligand in 2024 suggests a need for further updates to maintain comprehensive insights.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Insmed Incorporated and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Pharming Group N.V. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Perrigo Company plc and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Celldex Therapeutics, Inc.